Matthew Kronmiller

About Matthew Kronmiller

Matthew Kronmiller (age 38) is Executive Vice President of Strategy and Chief Business Officer at Galecto, Inc., a role he has held since October 2024 . He previously served as CEO of Bridge Medicines (Oct 2022–Oct 2024), Vice President at Bay City Capital (2011–Oct 2024), and as an Investment Banking Analyst at Bank of America Merrill Lynch; he holds a BS in Finance from Pennsylvania State University . Company filings do not disclose TSR, revenue growth, or EBITDA growth metrics tied specifically to his performance or compensation; Galecto provides limited executive compensation detail as an emerging growth company .

Past Roles

External Roles

Fixed Compensation

Performance Compensation

Note: The 2024 target bonus percentages disclosed apply to certain NEOs (CEO 60%, Interim CFO 30%, former CFO 40%, GC 40%); there is no disclosed target for the CBO role .

Equity Ownership & Alignment

Employment Terms

• Start date / tenure: Joined Galecto’s senior management in October 2024 and currently serves as EVP Strategy & CBO .
• Employment agreement: Not disclosed in proxy or 8‑K filings .
• Severance / change‑of‑control: Galecto’s Separation Benefits Plan covers named executive officers and “other members of management” designated by the Compensation Committee; detailed benefits are disclosed for the CEO and General Counsel, but coverage/terms for the CBO are not specified .
• Lock‑up and trading restrictions: In the Nov 10, 2025 Damora transaction, “certain directors and officers” (not named) signed 180‑day lock‑ups; the filing does not specify which officers were parties, so applicability to Kronmiller is not confirmed . Galecto’s insider trading policy imposes blackout/pre‑clearance and limits hedging/pledging without approval .

Performance & Track Record

• Strategic transactions and positioning:
  • Bridge Medicines asset purchase (Oct 7, 2024): Galecto acquired the BRM‑1420 dual ENL‑YEATS/FLT3 program for AML; Kronmiller was CEO of Bridge Medicines prior to joining Galecto .
  • Company evolution (Nov 10, 2025): Following the Damora merger and $285M private placement, Galecto’s “continuing leadership” explicitly includes Kronmiller as part of the senior team .
• Disclosures do not cite project‑specific outcomes or financial KPIs attributable to Kronmiller; risk factors emphasize the importance of retaining key executives, including Kronmiller, for execution .

Related Party & Governance Considerations

• Related party transaction context: The Bridge Medicines asset purchase involved entities affiliated with the Chair (Dr. Carl Goldfischer), who also serves as Executive Chairman of Bridge Medicines; the transaction consideration included common and Series A preferred stock and is subject to stockholder approvals and lock‑ups, mitigating near‑term sell pressure . Kronmiller’s prior role as Bridge Medicines CEO is disclosed in his biography .
• Compensation governance: The Compensation Committee (independent directors) oversees pay and retained Alpine Rewards as an advisor in 2024; Galecto has an adopted clawback policy .
• Pledging/hedging restrictions: Insider trading policy broadly prohibits short‑term speculation and pledging absent Audit Committee approval .

Investment Implications

• Alignment and trading signals: As of April 2025, Kronmiller’s disclosed equity exposure is limited (options for 1,433 shares exercisable within 60 days) and he reported no holdings at his October 2024 Form 3; no Form 4 sales were identified, suggesting low near‑term insider selling pressure from him personally . If he was a party to the 180‑day officer lock‑ups around the Nov 2025 Damora transaction (not named in the filing), that would further dampen near‑term selling, though applicability is not confirmed .
• Retention risk: He is named as a key executive in Galecto’s risk factors; severance/change‑of‑control coverage for the CBO under the Separation Benefits Plan is not specified, leaving some uncertainty on retention economics versus CEO/GC who have defined terms .
• Pay‑for‑performance visibility: Absent disclosed base/bonus targets or equity schedules for the CBO, investors have limited ability to assess Kronmiller’s incentive alignment beyond the general executive bonus framework and company‑wide clawback/insider‑trading controls .
• Execution: His background in transactions and investments (Bridge Medicines CEO; Bay City Capital VP) aligns with Galecto’s recent pipeline reshaping (Bridge asset purchase; Damora merger), positioning him as a key operator for BD and strategy through 2026–2027 milestones .

Appendix: Key Data Tables

Executive Background

Ownership & Transactions

Equity/Compensation Policies

ND = Not disclosed in company filings reviewed (DEF 14A 2025 and related 8‑Ks) .